Psivida (PSDV) PDUFA Date on October 17. 2013 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Psivida (PSDV) PDUFA Date on October 17. 2013

PSDV 1.220

+14.0%

Mar 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

PreviousNext

From: BioHero	8/27/2013 12:14:16 PM
	of 1

massdevice.com pSivida stands to reap revenues of $315 million annually from sales of its Iluvien drug/device combination for treating diabetic macular edema. "Therefore, based on the above projections, presuming that pSivida will get 315 million in revenue, the share price target of pSivida should be way north of $15.00," he wrote. "The lack of ample eye care investment options is definitely a problem in biotech. There are simply not any options to invest in back of the eye disease devices. Therefore, making it a very valuable biotech, which deserves a high valuation based on this. pSidiva is a huge takeover target for big pharma who want to dominate the ocular market. Pfizer (NYSE: PFE) and Bausch & Lomb come to mind, as Pfizer owns over 10% of pSidiva already, and pSidiva is licensing Vitrasert and Durasert to Bausch & Lomb. It would be in both companies interest to buyout pSidiva to dominate the ocular market," according to the article.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

PreviousNext